CalciMedica, Inc. (CALC)
$0.48+$0.01 (+1.34%) Today
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 248,972 | $200K |
| Grant or award | 22 | 15,070,613 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
50 Form 4 filings on record, the earliest from Nov 1, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Eric W. Roberts - Officer | Open-market purchase | Common Stock | 1,000 | $13.95 | $3K | |
| Eric W. Roberts - Officer | Open-market purchase | Common Stock | 2,000 | $13.60 | $5K | |
| Eric W. Roberts - Officer | Option exercise | Common Stock | 15,000 | $7.65 | $23K | |
| Eric W. Roberts - Officer | Option exercise | Employee Stock Option (Right to Buy) | 15,000 | $7.65 | $23K | |
| Sudarshan Hebbar - Officer | Open-market purchase | Common Stock | 1,584 | $12.92 | $4K | |
| Sudarshan Hebbar - Officer | Open-market purchase | Common Stock | 4,392 | $13.97 | $12K | |
| Kenneth A. Stauderman - Officer | Open-market sale | Common Stock | 1,000 | $18.25 | $4K | |
| Kenneth A. Stauderman - Officer | Open-market purchase | Common Stock | 1,000 | $19.80 | $4K | |
| Eric W. Roberts - Officer | Open-market purchase | Common Stock | 1,500 | $18.88 | $6K | |
 A. Rachel Leheny - Officer | Open-market purchase | Common Stock | 1,000 | $17.00 | $3K | |
| Eric W. Roberts - Officer | Open-market purchase | Common Stock | 1,500 | $16.85 | $5K | |
 Robert N. Wilson | Open-market purchase | Common Stock | 4,500 | $14.35 | $13K | |
| Eric W. Roberts - Officer | Open-market purchase | Common Stock | 2,000 | $14.40 | $6K | |
| Eric W. Roberts - Officer | Open-market purchase | Common Stock | 6,500 | $12.16 | $16K | |
| A. Rachel Leheny - Officer | Open-market purchase | Common Stock | 2,500 | $12.35 | $6K | |
| Eric W. Roberts - Officer | Open-market purchase | Common Stock | 5,000 | $8.02 | $8K | |
| Kenneth A. Stauderman - Officer | Open-market purchase | Common Stock | 1,000 | $9.25 | $2K | |
| Robert N. Wilson | Grant or award | Director Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Robert N. Wilson | Grant or award | Director Stock Option (Right to Buy) | 12,031 | $0.00 | - | |
| Robert N. Wilson | Grant or award | Director Stock Option (Right to Buy) | 36,562 | $0.00 | - | |
| Robert N. Wilson | Grant or award | Director Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Fred A. Middleton | Grant or award | Director Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Fred A. Middleton | Grant or award | Director Stock Option (Right to Buy) | 6,562 | $0.00 | - | |
| Fred A. Middleton | Grant or award | Director Stock Option (Right to Buy) | 19,687 | $0.00 | - | |
| Fred A. Middleton | Grant or award | Director Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Fred A. Middleton | Open-market purchase | Common Stock | 4,800 | $13.25 | $13K | |
| Sanderling Venture Partners VI Co Investment Fund LP | Open-market purchase | Common Stock | 86,867 | $18.75 | $326K | |
| Sanderling Venture Partners VI Co Investment Fund LP | Open-market purchase | Common Stock | 877 | $18.75 | $3K | |
| Fred A. Middleton | Open-market purchase | Common Stock | 20,000 | $18.75 | $75K | |
| Fred A. Middleton | Open-market purchase | Common Stock | 86,867 | $18.75 | $326K | |
| Fred A. Middleton | Open-market purchase | Common Stock | 877 | $18.75 | $3K | |
| A. Rachel Leheny - Officer | Open-market purchase | Common Stock | 20,000 | $18.75 | $75K | |
| Eric W. Roberts - Officer | Open-market purchase | Common Stock | 53,333 | $18.75 | $200K | |
| Robert N. Wilson | Open-market purchase | Common Stock | 53,333 | $18.75 | $200K |
This is as far as the anonymous view goes. Create a free account for all 50 CALC filings on record.
CalciMedica, Inc. (CALC) had 15 insider filings in the last 90 days, with the most recent on 2026-08-24. The full record for CALC runs to 50 Form 4 filings, the earliest from 2024-11-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
1 insider purchase of CALC was filed in the last 90 days, totaling $200K.
No insider sales of CALC were filed in the last 90 days. 1 sale is on record for this company.
This page tracks CALC Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CALC to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
